Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued.
Zymeworks's earnings per share for Q2 sits at $-0.75, whereas in Q1, they were at -0.34. Cross Country Healthcare saw a decrease in earnings per share from 0.84 in Q1 to $0.69 now. Agile Therapeutics has reported Q2 earnings per share at $-3.1, which has increased by 60.05% compared to Q1, which was -7.76. Leafly Holdings has reported Q2 earnings per share at $-0.8, which has increased by 71.43% compared to Q1, which was -2.8. Assertio Holdings saw a decrease in earnings per share from 0.29 in Q1 to $0.19 now.
These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector.